Lineage Cell Therapeutics, Inc. (LCTX) Balance Sheet

NYSE American: LCTXAssets, liabilities, debt and equity over 10 years.

LCTX balance sheet, 2025

December 31, 2025 · U.S. dollars

$112.6M assets = $69.2M liabilities + $43.3M equity

What it owns$112.6MCash & ST investments: $55.8M (49.5%)Cash & ST investments$55.8M · 50%Receivables: $1.6M (1.4%)Other current: $1.8M (1.6%)PP&E: $4.7M (4.2%)Goodwill & intangibles: $42.4M (37.6%)Goodwill & intangibles$42.4M · 38%Other non-current: $6.4M (5.6%)=How it is financed$112.6MCurrent liabilities: $11.4M (10.1%)Current liabilities $11.4MOther LT liabilities: $57.9M (51.4%)Other LT liabilities$57.9M · 51%Shareholders’ equity: $43.3M (38.5%)Shareholders’ equity$43.3M · 39%

Both columns are drawn to the same scale: what LCTX owns equals what it owes plus shareholders’ equity. Hover a block for its value.

LCTX financial health

Current ratio5.20
Comfortable · current assets cover current liabilities 5.20×
Debt / equity0.05
Low leverage · $0.05 of debt for each $1 of equity
Equity / assets39.6%
Balanced · of assets funded by shareholders
Cash / debt2,306.0%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles37.6%
Acquisition-heavy · of total assets

Descriptive bands, not a rating. Fiscal 2025.

LCTX balance sheet trends, 2016–2025

Lineage Cell Therapeutics, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$142.6M2016$112.6M2025−2.6%/yr
Total liabilities$12.1M2016$69.2M2025+21.4%/yr
Shareholders’ equity$117.9M2016$44.5M2025−10.3%/yr
Cash & short-term investments$22.7M2016$55.8M2025+10.5%/yr
Total debt$4.0M2016$2.4M2025−5.4%/yr
Net cash (debt)$18.7M2016$53.4M2025+$34.6M
Working capital$16.8M2016$47.8M2025+$31.0M
Book value per share$1.182016$0.192025−18.2%/yr
Current ratio2.9020165.202025+2.31
Debt / equity0.0320160.052025+0.02
Shares outstanding99.6M2016230.1M2025+9.8%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

LCTX assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

LCTX liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

LCTX debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

LCTX balance sheet

Lineage Cell Therapeutics, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$55.8M$47.8M$35.5M$57.9M$58.4M$41.6M$30.7M$30.7M$38.2M$22.7M
Cash & equivalents$40.8M$45.8M$35.4M$11.4M$55.7M$32.6M$9.5M$23.6M$36.8M$22.1M
Short-term investments$15.0M$2.0M$50,000$46.5M$2.6M$9.0M$21.2M$7.2M$1.3M$627,000
Receivables$1.6M$638,000$745,000$297,000$51.1M$4,000$24.7M$3.7M$3.0M$1.2M
Inventory$0$0$0$1$0$0$1$1$1$0
Other current assets$1.8M$2.6M$2.2M$1.8M$2.1M$2.4M$2.1M$1.9M$1.4M$1.8M
Total current assets$59.2M$51.0M$38.4M$60.0M$111.5M$44.0M$57.5M$36.4M$42.6M$25.6M
Property, plant & equipment (net)$4.7M$4.4M$4.8M$5.7M$4.9M$5.6M$8.2M$5.8M$5.5M$5.5M
Goodwill & intangible assets$42.4M$57.2M$57.2M$57.4M$57.5M$57.7M$58.9M$3.1M$6.9M$10.2M
Long-term investments$0$0$0$0$0$0$0$55.8M$117.2M$100.0M
Other non-current assets$6.4M$614,000$577,000$627,000$630,000$616,000$864,000$505,000$1.0M$1.1M
Total assets$112.6M$113.2M$101.0M$123.7M$174.5M$107.9M$125.5M$101.7M$173.2M$142.6M
Liabilities
Accounts payable$2.3M$1.2M$2.0M$2.4M$3.5M$2.6M$2.4M$2.4M$938,000$1.6M
Short-term debt$853,000$1.2M$882,000$952,000$831,000$1.3M$1.2M$307,000$364,000$1.1M
Deferred revenue$3.3M$7.4M$10.8M$9.4M$18.1M$193,000$45,000$42,000$797,000$572,000
Total current liabilities$11.4M$14.0M$18.0M$19.0M$47.1M$7.8M$6.5M$6.8M$6.9M$8.8M
Long-term debt$0$0$0$0$0$0$77,000$2.0M$1.2M$2.8M
Lease obligations$2.4M$2.5M$3.0M$3.9M$2.8M$3.3M$5.2M$2.2M$1.4M$1.9M
Other long-term liabilities$57.9M$22.2M$21.0M$32.7M$36.5M$5.1M$7.7M$644,000$930,000$366,000
Total liabilities$69.2M$36.2M$39.0M$51.7M$83.6M$12.8M$14.2M$9.4M$9.0M$12.1M
Shareholders' equity
Common stock & paid-in capital$515.5M$484.7M$451.3M$440.3M$434.5M$393.9M$387.1M$354.3M$378.5M$317.9M
Retained earnings (deficit)−$467.0M−$403.5M−$384.9M−$363.4M−$337.1M−$294.1M−$273.4M−$261.9M−$216.3M−$196.3M
Treasury stock—————————−$2.9M
Accumulated other comprehensive income−$3.9M−$2.9M−$3.1M−$3.6M−$5.2M−$3.7M−$681,000$1.4M$451,000−$738,000
Minority interest−$1.2M−$1.4M−$1.4M−$1.4M−$1.3M−$1.1M−$1.7M−$1.6M——
Total shareholders' equity$44.5M$78.4M$63.4M$73.3M$92.2M$96.2M$113.0M$93.8M$162.6M$117.9M
Key figures
Total debt$2.4M$2.5M$3.0M$3.9M$2.8M$3.8M$5.2M$2.3M$1.5M$4.0M
Net cash (debt)$53.4M$45.3M$32.5M$54.0M$55.6M$37.7M$25.5M$28.5M$36.6M$18.7M
Working capital$47.8M$37.0M$20.5M$41.0M$64.4M$36.2M$51.0M$29.5M$35.7M$16.8M
Tangible book value$2.2M$21.2M$6.2M$16.0M$34.7M$38.5M$54.0M$90.7M$155.7M$107.7M
Book value per share$0.19$0.39$0.37$0.43$0.56$0.64$0.78$0.74$1.42$1.18
Shares outstanding230.1M200.2M172.7M169.8M164.5M150.0M145.5M126.9M114.5M99.6M
Current ratio5.203.652.143.162.375.668.865.346.202.90
Quick ratio5.043.472.023.062.325.358.545.065.992.70
Debt / equity0.050.030.050.050.030.040.050.020.010.03
Equity / assets39.6%69.2%62.8%59.3%52.8%89.1%90.0%92.3%93.9%82.7%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 5, 2026); data from EODHD.

LCTX financial position

At the end of fiscal 2025 (December 31, 2025), Lineage Cell Therapeutics had total assets of $112.6 million (down 0.6% from a year earlier), total liabilities of $69.2 million and shareholders' equity of $44.5 million. It held $55.8 million in cash and short-term investments against $2.4 million of debt, a net cash position of $53.4 million. Its current ratio was 5.20. In the latest quarter (ended June 30, 2026) total assets were $106.2 million and equity $60.9 million.

Related: LCTX income statement, LCTX cash flow statement, LCTX key metrics. See the LCTX stock overview for the latest quote and news.

LCTX balance sheet FAQ

What are Lineage Cell Therapeutics's total assets?

Lineage Cell Therapeutics reported total assets of $112.6 million at the end of fiscal 2025 (December 31, 2025), compared with $113.2 million a year earlier.

How much debt does Lineage Cell Therapeutics have?

Lineage Cell Therapeutics had $2.4 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.05.

How much cash does Lineage Cell Therapeutics have?

Lineage Cell Therapeutics held $55.8 million in cash and short-term investments at the end of fiscal 2025; with $2.4 million of debt that is net cash of $53.4 million.

What is Lineage Cell Therapeutics's book value?

Lineage Cell Therapeutics's shareholders' equity (book value) was $44.5 million at the end of fiscal 2025, or $0.19 per share.

What is Lineage Cell Therapeutics's current ratio?

Lineage Cell Therapeutics had current assets of $59.2 million and current liabilities of $11.4 million, a current ratio of 5.20 (it can cover its short-term obligations).

How much goodwill does Lineage Cell Therapeutics have?

Lineage Cell Therapeutics carried $42.4 million of goodwill and intangible assets, 37.6% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet